These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Therapy of some diseases of the myocardium with potassium aspartate]. Capritti AG Minerva Med; 1967 Apr; 58(33):1512-5. PubMed ID: 6026634 [No Abstract] [Full Text] [Related]
46. [Blood coagulation state in destructive pulmonary tuberculosis patients under different methods of chemotherapy]. Sagalovich VIa; Beresneva RE; Ivanova VB Probl Tuberk; 1981 May; (5):30-4. PubMed ID: 7255385 [No Abstract] [Full Text] [Related]
47. Citrulline, Viagra and BiDil--bad medicine. Czp A Altern Med Rev; 2005 Dec; 10(4):265-7. PubMed ID: 16400750 [No Abstract] [Full Text] [Related]
49. [Dynamics of various immunobiochemical and encephalographic indices during polychemotherapy of pulmonary tuberculosis patients]. Sagalovich VIa; Medunitsyna ND; Andrzheiuk NI; Chelnokova NV; Sagalovich AV Probl Tuberk; 1982 Feb; (2):36-41. PubMed ID: 7063477 [No Abstract] [Full Text] [Related]
50. Clinical experience with isobutol: a new molecular combination of ethambutol-INH. Leonin TA Kekkaku; 1981 Feb; 56(2):63-8. PubMed ID: 7265605 [No Abstract] [Full Text] [Related]
51. Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline. Smith HA; Canter JA; Christian KG; Drinkwater DC; Scholl FG; Christman BW; Rice GD; Barr FE; Summar ML J Thorac Cardiovasc Surg; 2006 Jul; 132(1):58-65. PubMed ID: 16798303 [TBL] [Abstract][Full Text] [Related]
52. [The problem of fatigue and its treatment]. Pino P Minerva Med; 1967 Feb; 58(15):547-52. PubMed ID: 5336590 [No Abstract] [Full Text] [Related]
53. [Enhancing the effectiveness of chemotherapy for pulmonary tuberculosis by phytotherapy in patients with different genetic markers]. Tashpulatova FK; Ubaĭdullaev AM Probl Tuberk; 2002; (12):46-9. PubMed ID: 12611337 [No Abstract] [Full Text] [Related]
54. [L-transformation of the mycobacterial population in the process of treating patients with newly detected destructive pulmonary tuberculosis]. Khomenko AG; Karachunskiĭ MA; Dorozhkova IR; Chukanov VI; Balta IuE Probl Tuberk; 1980 Feb; (2):18-23. PubMed ID: 6769110 [No Abstract] [Full Text] [Related]
55. [Clinical aspects and therapy of peripheral lymph node tuberculosis today]. Jung HD; Merkel S Dermatol Monatsschr; 1984; 170(4):225-31. PubMed ID: 6734863 [No Abstract] [Full Text] [Related]
56. [Rapid intravenous injections of an isoniazid solution in the combination treatment of pulmonary tuberculosis]. Radzinskiĭ AG; Lisikhin VN Voen Med Zh; 1981 Mar; (3):34-6. PubMed ID: 7222489 [No Abstract] [Full Text] [Related]
57. Three-month retreatment in pulmonary tuberculosis. Chinachoti T; Jittinandana A J Med Assoc Thai; 1983 May; 66(5):274-7. PubMed ID: 6875419 [No Abstract] [Full Text] [Related]
58. [New cases of pulmonary tuberculosis treatment within DOTS strategy]. Zhangireev AA; Ismailov ShSh; Berikova EM Probl Tuberk; 2000; (3):23-5. PubMed ID: 10900979 [TBL] [Abstract][Full Text] [Related]
59. [Bacterio-clinical identifications. (VI). Recapitulative study of the paucibacillary state in treated tuberculosis patients. (According to 48,000 bacteriologic tests performed during continuous antitubercular treatment in a sanatorium)]. Martin-Lalande J Rev Tuberc Pneumol (Paris); 1966 Jan; 30(1):71-102. PubMed ID: 5935137 [No Abstract] [Full Text] [Related]
60. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon. Kuaban C; Bercion R; Koulla-Shiro S East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]